ORYZON Initiates a New Project to Explore the Efficacy of Vafidemstat in the Treatment of Schizophrenia – BioSpace

MADRID, Spain and CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- ORYZON Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its project entitled VENCER: Vafidemstat: Efficacy in the treatment against Schizophrenia and other related pathologies has been approved for funding by the Spanish Ministry of Science and Innovation under the 2019 call of the governmental R&D RETOS-COLABORACION program. The company will carry out this project in Collaboration with the Group of Psychiatry, Mental Health and Addictions of the Research Institute of Vall dHebrn (VHIR) in Barcelona. The project has an initial global budget of 1,129,716.

This new public funding, structured in the form of a preferential long-term soft-loan for companies and non-reimbursable grants for the participating Public Research Organizations, comprises a loan to Oryzon for 688,517 plus a grant of 332,601 to the VHIR. The project will explore the efficacy of vafidemstat, a Phase II drug in development in central nervous system (CNS) disorders, in the treatment of patients with schizophrenia or related psychiatric disorders. This funding will partially cover the activities of the project, including activities related to a Phase II clinical study in schizophrenia patients and a set of additional research to gain further insight into the activity of vafidemstat in these psychiatric patients. The project is foreseen to last a maximum of 39 months, with a start scheduled for next October 1, 2020.

The Group of Psychiatry, Mental Health and Addictions of the Research Institute of Vall dHebrn (VHIR) led by Dr Ramos-Quiroga and Oryzon have already successfully collaborated on a recent Phase IIa clinical trial called REIMAGINE, where vafidemstat was shown to reduce agitation and aggression in psychiatric patients with borderline personality disorder, autism, and attention deficit hyperactivity disorder (ADHD), as well as to improve their general clinical condition. In addition to the interest that vafidemstats mechanism of action has for general population with schizophrenia, independent research results recently published by U.S. universities show that some genetic mutations involved in the evolution of schizophrenia can be mitigated by Oryzons LSD1 inhibitors.

Roger Bullock, Chief Medical Officer of Oryzon, commented: "This new study in schizophrenia patients will continue the efforts made in the last three years to demonstrate the ability of vafidemstat to exert a positive effect in the treatment of disorders of the behavior in a wide range of neurodegenerative and psychiatric indications and we hope that in the future it will provide positive results in these patients such as those already presented in the REIMAGINE and REIMAGINE-AD trials in patients with borderline personality disorder, autism spectrum disorder or attention deficit hyperactivity disorder and in patients with Alzheimer's disease.

Dr. Ramos-Quiroga, Head of the Group of Psychiatry, Mental Health and Addictions of the Research Institute of Vall dHebrn (VHIR) said, The epigenetic modulation exerted by vafidemstat has opened up a new paradigm in the search for safer and more efficacious treatments for mental disorders where neurodevelopment dysfunctions co-exist with environmental triggers.

About Oryzon Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzons LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States. For more information, visit http://www.oryzon.com

About Vafidemstat Vafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimers disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed a Phase IIa clinical trial in aggressiveness in patients with different psychiatric disorders (REIMAGINE) and in aggressive/agitated patients with moderate or severe AD (REIMAGINE-AD), with positive preliminary clinical results reported. Additional Phase IIa clinical trials with vafidemstat are ongoing in patients with Mild to Moderate AD (ETHERAL), where a significant reduction of the inflammatory biomarker YKL40 has been observed after 6 months of treatment, and in Relapse-Remitting and Secondary Progressive MS (SATEEN).

FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words expects, anticipates, believes, intends, estimates and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisin Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzons securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzons securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

Go here to read the rest:
ORYZON Initiates a New Project to Explore the Efficacy of Vafidemstat in the Treatment of Schizophrenia - BioSpace